Skip directly to content

The 21st Century Cures Act and a right-wing war on regulations are direct threats to FDA evidentiary requirements for drugs, biologics, and devices

By Tim Horn and Suraj Madoori

What could possibly be wrong with legislation beamishly called the 21st Century Cures Act? Signed by President Obama during his final days in office, the bill’s appeal and broad bipartisan support are understandable.

How the Trump administration’s anti-immigrant stance threatens human rights, public health, and the lives of people living with TB

By Erica Lessem and Suraj Madoori

Perhaps the most recognizable symbol of the current presidential administration and the campaign that led Donald Trump to the White House is the wall. In 2015, then-candidate Trump first announced his intention to build a wall between the United States and Mexico.

Lingering Republican threats to the ACA and Medicaid do no favors for America’s working poor    

By Annette Gaudino

The 2016 election is in large part a story of the failure of existing health policy to adequately address a health crisis among the working class. The largest voter margins in favor of Trump comprise many people in poor health. This includes the opioid overdose epidemic currently occurring among predominantly white, suburban, and rural communities battered by deindustrialization and dimmed economic prospects.

Trump’s early tough talk on drug pricing is now a pro-industry, anti-regulation GOP dreamscape

By Bryn Gay

Unaffordable drug prices were a hot-button topic on the 2016 U.S. presidential campaign trail and remain a significant source of frustration among Democrats and Republicans in Congress. This common ground, backed by public opinion (see sidebar), can be leveraged to steer drug-pricing legislation and regulations toward truly bold initiatives that prioritize affordable treatment access.

Click for larger image

Within his first two

Mobilizing to defend biomedical research investments and scientific integrity as essential for public health, safety, and well-being

By Kenyon Farrow and Mike Frick

One of the more memorable moments of resistance to the Trump administration’s and GOP-controlled Congress’ plan to repeal the Affordable Care Act (ACA) took place on February 9, 2017 in Murfreesboro, Tennessee, at a town hall meeting organized by Republican Representative Diane Black.

Maintaining and expanding the accomplishments of the past depend on a fight for their survival and growth—now more than ever

By Mark Harrington

Today’s political situation with respect to the struggle to end HIV/AIDS, to treat all of those infected, and to reduce new transmission of the virus to zero, is facing new and unprecedented challenges.

On Sunday February 12, 2017 in Seattle, the AIDS Treatment Activists CoalitionAVAC, the DARE Community Advisory Board, the defeatHIV Community Advisory Board, European AIDS Treatment GroupProject Inform and TAG co-sponsored a community workshop on HIV cure research. The workshop has become an annual event that takes place immediately prior to the Conference on Retroviruses and Opportunistic Infections (CROI). Available slide presentations are posted below. 

Online reports

March 31, 2017 ­– With growing bipartisan support for feasible measures to control skyrocketing prescription medication costs, a Health Affairs Blog post published today describes four proposals to strengthen and modernize cost control measures that already exist in the United States. The Blog post, co-authored by Tim Horn, Treatment Action Group's Deputy Executive Director of HIV & HCV Programs,  and Sean Dickson, Senior Manager, Health Systems Integration, at NASTAD (National Alliance of State and Territorial AIDS Directors), is based on a critical analysis, Tackling Drug Costs: A 100-Day

HIV, TB, HCV, Global Health and Research Communities Call on Congress to Protect the Fogarty International Center

Community Sign-on Letter to Protect the NIH Fogarty International Center with Signatures

March 30, 2017

Dear Majority Leader McConnell, Minority Leader Schumer, Speaker Ryan, and Democratic Leader Pelosi: We the undersigned urge Congress to reject devastating funding cuts to the National Institutes of Health (NIH) proposed under the President’s Fiscal Year (FY) 2018 “skinny budget,” released on March 16, 2017. Of grave concern is the targeted elimination of the Fogarty International Center at NIH.

Mark Harrington's keynote speech at the Critical Path to TB Drug Regimens meeting

March 20, 2017 – Mark Harrington, TAG's executive director, included in his keynote speech at the Critical Path to TB Drug Regimens meeting the importance of public and private sector funding for research, of thoughtful regulatory strategies, and of rapid uptake of new, evidence-based tools.